English

QLIFE HOLDING AB, YEAR END REPORT 2021, Q4

Report this content

Ninety percent full year sales growth

FINANCIAL SUMMARY – FOURTH QUARTER 2021

  • Revenue in the period amounted to kSEK 12,084 (9,122). Revenue regards sales of Egoo.Health devices and COVID-19 test capsules.
  • EBITDA for the period amounted to kSEK -11,850 (-6,501), and net loss kSEK -15,805 (-7,602).
  • The total cash flow in the fourth quarter amounted to kSEK -9,307 (-1,013).
  • Earnings per share before/after dilution for the fourth quarter amounted to SEK -1.02 (-0.68), calculated on weighted average number of shares in the period.

 FINANCIAL SUMMARY – JANUARY -DECEMBER 2021

  • Revenue in the period amounted to kSEK 39,613 (20,750). Revenue includes sales of COVID-19 tests from the test service center as well as Egoo.Health devices and capsules for decentralized testing.
  • EBITDA for the period amounted to kSEK -35,383 (-19,422), and net loss kSEK -48,838 (-20,200).
  • In the second quarter, Qlife raised MSEK 121.2 (after issuance costs) through a directed share issue and the exercise of TO1 warrants.
  • The total cash flow for the full year amounted to kSEK 52,600 (15,253).
  • Shareholders equity as of 31 December amounted to kSEK 163,179 (89,549).
  • Earnings per share before/after dilution for the year amounted to SEK -3.83 (-1.91).

SIGNIFICANT EVENTS – FOURTH QUARTER 2021

  • Qlife signed an agreement with FIND, the global alliance for diagnostics, for a funding of MUSD 3.45 for a 12-month project to develop a novel two-in-one assay for the detection of influenza and SARS-CoV-2 viruses in decentralized healthcare settings. In December, the first installment was paid out to Qlife from FIND, amounting to MSEK 12.
  • In November, the scientific study of the company’s COVID-19 on the Egoo platform test was accepted and subsequently published in Natures Scientific Reports. (https://www.nature.com/srep/).
  • Qlife recruited Kasper Damgaard Rousøe as new Chief Financial Officer (CFO) for Qlife Holding AB and subsidiary Qlife Aps. Kasper will join Qlife as per 1 March.
  • In accordance with the decision at Qlife Holding’s Annual General assembly a Nomination committee was convened, consisting of: Anita Otterheim Hjalmarsson, Sören Skjärbäk, Lars Bangsgaard and Mette Gross.

​​​​​​​Link to report: https://qlifeholding.com/sv/investerare/finansiella-rapporter

This disclosure contains information that Qlife Holding AB is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 17-02-2022 09:30 CET.

For more information please contact:

Thomas Warthoe, CEO
tw@egoo.health
+45 21 63 35 34

Qlife is a medical device company that seeks to revolutionize the clinical biomarker market for whole blood testing by taking it out of the lab and into the homes. This will facilitate easy access to blood sample results and in turn facilitate increased monitoring of parameters that enables care improvement.

Shares for Qlife are being traded on Nasdaq First North Growth Market in Stockholm with G&W Fondkommission as certified advisor (phone: +46 (0) 8-503 000 50, e-mail: ca@gwkapital.se).

Read more on Egoo.health, Qlifeholding.com or follow us on LinkedIn.

 

Subscribe

Documents & Links